Daniel S. Lorrain sold $44k of CTNM
Chief Scientific Officer at Contineum Therapeutics, Inc.. 4,170 shares at an average of $10.44, traded Jan 5, 2026, filed Jan 6, 2026.
Score components
- +15RoleOfficer
- +6Trade size$44k at market
- 0Share of holdings soldSold 2.5% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +52.6%, 3m +34.1%, 6m +53.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-26-000616, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -3,670 | $10.35 | $38k | 160,722 | Jan 6, 2026 |
| Jan 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -500 | $11.13 | $5,565 | 160,222 | Jan 6, 2026 |
Related signals
Other insiders at Contineum Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 1Weak | Contineum Therapeutics, Inc. | Carmine N. Stengone CEO and President | $41k 2,500 shares | -13% | |
| 1Weak | Contineum Therapeutics, Inc. | Carmine N. Stengone CEO and President | $40k 2,500 shares | -13% | |
| 0Weak | Contineum Therapeutics, Inc. | Daniel S. Lorrain Chief Scientific Officer | $17k 1,040 shares | -1% | |
| 16Weak | Contineum Therapeutics, Inc. | Carmine N. Stengone CEO and President | $40k 2,500 shares | -13% | |
| 19Weak | Contineum Therapeutics, Inc. | Daniel S. Lorrain Chief Scientific Officer | $595k 37,179 shares | -22% | |
| 26Weak | Contineum Therapeutics, Inc. | Carmine N. Stengone CEO and President | $160k 10,000 shares | -37% | |
| 26Weak | Contineum Therapeutics, Inc. | Tim Watkins CMO & Head of Development | $174k 10,833 shares | -55% | |
| 2Weak | Contineum Therapeutics, Inc. | Daniel S. Lorrain Chief Scientific Officer | $55k 4,170 shares | -3% | |
| 2Weak | Contineum Therapeutics, Inc. | Daniel S. Lorrain Chief Scientific Officer | $55k 4,170 shares | -3% | |
| 2Weak | Contineum Therapeutics, Inc. | Daniel S. Lorrain Chief Scientific Officer | $56k 4,170 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.